GlassScriptPhysician profile
Amy J Blake
NPI 1467062950
$17,189.45
in general payments reported to CMS, 2019-2025
18 companies · $4,599 in 2025
The $4,599 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $616 · 2022: $7,981 · 2023: $876 · 2024: $3,117 · 2025: $4,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843 · Travel and Lodging: $2,352 · Consulting Fee: $1,870 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440 · Education: $87.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,842.74 |
| Travel and Lodging | $2,351.84 |
| Consulting Fee | $1,870.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
| Education | $87.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $7,405.49 | 2022-2025 | Ojjaara |
| Alnylam Pharmaceuticals INC. | $6,528.88 | 2022-2025 | Amvuttra |
| Beigene USA, INC. | $623.67 | 2021-2025 | Brukinsa |
| Janssen Biotech, INC. | $563.43 | 2021-2025 | Rybrevant, Carvykti, Talvey |
| Adaptive Biotechnologies Corporation | $471.18 | 2022-2023 | Clonoseq |
| Amgen INC. | $352.22 | 2021-2024 | Blincyto, Xgeva |
| Pfizer INC. | $254.01 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $249.30 | 2024 | Reblozyl |
| Genentech USA, INC. | $138.66 | 2023 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $122.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.62 | 2022 | |
| Lilly USA, LLC | $87.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $78.72 | 2025 | |
| Celgene Corporation | $67.65 | 2023-2024 | Pomalyst |
| Jazz Pharmaceuticals INC. | $54.03 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $39.10 | 2021 | |
| Kite Pharma, INC. | $31.75 | 2025 | Yescarta |
| Janssen Scientific Affairs, LLC | $28.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.